The permission of Lenvima, a thyroid-targeted anticancer drug, will be changed based on the results of a six-year post-marketing survey conducted in Korea. The Ministry of Food and Drug Safety will prepare a change order (proposal) based on the results of the post-marketing investigation of Lenvima by Eisai Korea and conduct an opinion inquiry by the 3rd of next month.

Lenvima treated patients with localized recurrent or metastatic progressive differentiated thyroid cancer who did not respond to radioactive iodine in October 2015. It obtained an item license in Korea for its effectiveness. Later, Lenvima's primary treatment for hepatocellular carcinoma and KIF5B-RET-positive lung adenocarcinoma clinica